Genprex is a clinical-stage gene therapy company with no approved products or revenue, focused on treatments for cancer and diabetes. Its lead asset is REQORSA (quaratusugene ozeplasmid), a gene therapy for lung cancer that delivers a functioning copy of the TUSC2 tumor suppressor gene — absent or reduced in most lung cancers — directly into cancer cells via IV injection. REQORSA works through multiple mechanisms: disrupting cancer cell metabolism, triggering apoptosis, blocking tumor growth signaling, and enhancing immune response. REQORSA is always developed in combination with already-approved drugs, not as a standalone therapy. The two active clinical programs are Acclaim-1, combining REQORSA with AstraZeneca's Tagrisso for EGFR-mutant non-small cell lung cancer patients who have progressed on Tagrisso, and Acclaim-3, combining REQORSA with Genentech's Tecentriq as maintenance therapy for extensive-stage small cell lung cancer. Both are Phase 2 trials with interim analyses expected in the second half of 2026. Genprex's secondary pipeline asset is GPX-002, a preclinical gene therapy aimed at reprogramming pancreatic alpha cells into insulin-producing cells for both Type 1 and Type 2 diabetes, housed in a wholly-owned subsidiary called Convergen Biotech. Genprex has no revenue and funds operations entirely through equity issuances, primarily via an at-the-market offering program. The company has flagged going concern doubt and faces ongoing Nasdaq compliance risk.